SynthesisJournal of environmental and public health2023
The Role of C-Reactive Protein in the Prognosis of Prostate Cancer: A Meta-Analysis.
Synthesis in Journal of environmental and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance of C-reactive protein in patients with cervical cancer: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Association between periodontitis severity and prostate-specific antigen levels using the NHANES data.Journal of periodontology · 2025Article
- Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide.Scientific reports · 2023Article
- Prognostic value of baseline C-reactive protein in diffuse large B-cell lymphoma: a systematic review and meta-analysis.Translational cancer research · 2023Article
- Retracted: The Role of C-Reactive Protein in the Prognosis of Prostate Cancer: A Meta-Analysis.Journal of environmental and public health · 2023Article
Corrections and comments
- Retraction · 2023-12-13Compromised Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the role of C-reactive protein (CRP) in the prognosis of prostate cancer (PCa). Methods: The studies related to C-reactive protein and prostate cancer were searched by computer, including PubMed and Web of Science. The retrieval time was from the establishment of the database to August 2022. QUADAS score was employed to assess the studies' quality, funnel plot was employed to analyze the bias of the included studies, and RevMan and STATA statistical software programs were used to draw forest maps to represent the analysis results. Results: In the initial examination, 432 articles were obtained. After removing the duplicate articles, reading the abstract and theme, and then reading the full text, 12 articles finally met the inclusion criteria. The results revealed that serum C-reactive protein (CRP) levels were associated with overall survival (OS) in patients with PCa (OR = 1.47 [1.19, 1.82], Conclusions: CRP levels are associated with PCa patients' OS. High CRP levels have an elevated incidence of PCa, but there was no obvious distinction in circulating CRP levels between patients with prostate cancer and healthy controls. Therefore, C-reactive protein has certain reference value for judging the prognosis of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.